Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS).
View the full article